Arrowhead Pharmaceuticals, Inc. (ARWR) Financials
NASDAQ:ARWRMarket Cap
2.92B
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| 290,266 | 175,000 | 382,000 | 158,333 | 31,407,709 | 16,142,321 | 168,795,577 | 87,992,066 | 138,287,000 | 243,231,000 | |
| -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| 290,266 | 175,000 | 382,000 | 158,333 | 31,407,709 | 16,142,321 | 168,795,577 | 87,992,066 | 138,287,000 | 243,231,000 | |
| 8,705,627 | 23,138,050 | 57,410,147 | 41,454,452 | 31,690,298 | 52,968,505 | 81,048,686 | 128,874,979 | 206,342,000 | 297,307,000 | |
| -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |
| 11,692,804 | 24,419,536 | 34,718,089 | 40,998,209 | 32,022,880 | 19,110,051 | 26,556,257 | 52,275,890 | 80,981,000 | 124,431,000 | |
| 11,692,804 | 24,419,536 | 34,718,089 | 40,998,209 | 32,022,880 | 19,110,051 | 26,556,257 | 52,275,890 | 80,981,000 | 124,431,000 | |
| 23,571,495 | 51,278,899 | 96,355,976 | 79,850,242 | 68,403,618 | 72,078,556 | 107,604,943 | 181,150,869 | 287,323,000 | 421,738,000 | |
| -24,589,276 | -53,276,286 | -95,973,976 | -81,742,726 | -36,995,909 | -55,936,235 | 61,190,634 | -93,158,803 | -149,036,000 | -178,507,000 | |
| -8,323,940 | -8,261,706 | 3,306,336 | -2,294,487 | 2,202,886 | 439,634 | 6,957,768 | 8,607,977 | 8,190,000 | 5,798,000 | |
| -14,844,993 | -41,493,320 | -96,526,231 | -74,080,025 | -33,195,831 | -51,669,101 | 65,629,778 | -87,216,539 | -140,769,000 | -178,507,000 | |
| 1,751,412 | 1,345,655 | 2,336,207 | 3,260,045 | 4,690,440 | 4,699,275 | 4,439,144 | 5,942,264 | 8,267,000 | 10,421,000 | |
| -- | -- | -- | -- | -- | -- | -- | -- | -- | 5,033,000 | |
| -- | 645,493,000 | 729,158,000 | 265,794,000 | 415,128,000 | 1,048,523,000 | 6,957,768,000 | 9,190,501,000 | 6,120,000 | 5,033,000 | |
| -31,703,079 | -58,720,112 | -91,938,482 | -81,720,602 | -34,377,895 | -54,448,078 | 68,148,402 | -84,550,826 | -140,846,000 | -172,709,000 | |
| 6,222,944 | 5,300 | 2,400 | 2,400 | 2,400 | 2,400 | 173,553 | 2,400 | 2,000 | 3,785,000 | |
| -31,143,289 | -58,630,190 | -91,940,882 | -81,723,002 | -34,380,295 | -54,450,478 | 67,974,849 | -84,553,226 | -140,848,000 | -176,494,000 | |
| -1.3 | -1.25 | -1.6 | -1.34 | -0.47 | -0.65 | 0.72 | -0.84 | -1.36 | -1.67 | |
| -1.3 | -1.25 | -1.6 | -1.34 | -0.47 | -0.65 | 0.69 | -0.84 | -1.36 | -1.67 | |
| 24,002,224 | 46,933,030 | 57,358,442 | 61,050,880 | 73,898,598 | 83,638,469 | 93,859,000 | 100,722,000 | 103,745,000 | 105,426,000 | |
| 24,002,224 | 46,933,030 | 57,358,442 | 61,050,880 | 73,898,598 | 83,638,469 | 98,608,000 | 100,722,000 | 103,745,000 | 105,426,000 | |
| 23,571,495 | 51,278,899 | 96,355,976 | 79,850,242 | 68,403,618 | 72,078,556 | 107,604,943 | 181,150,869 | 287,323,000 | 421,738,000 | |
| -997,975 | 82,092 | 417,874 | 57,352 | 1,312,524 | 7,493 | -- | -582,524 | 2,070,000 | 5,798,000 |
Key Facts
Industry
Biotechnology
Sector
Healthcare
Headquarters
Pasadena, CA, US
Website
CEO
Dr. Christopher R. Anzalone Ph.D.
Employees
397
About the Company
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.